JP2009525984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525984A5 JP2009525984A5 JP2008553518A JP2008553518A JP2009525984A5 JP 2009525984 A5 JP2009525984 A5 JP 2009525984A5 JP 2008553518 A JP2008553518 A JP 2008553518A JP 2008553518 A JP2008553518 A JP 2008553518A JP 2009525984 A5 JP2009525984 A5 JP 2009525984A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- ylmethoxy
- isoxazol
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KZSBGQYBMRPUGK-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]-1-propan-2-ylindole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C(C)C)C=C(C3=CC=2)C(O)=O)C=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl KZSBGQYBMRPUGK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- XWDMAGXYQPWSDN-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SC=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F XWDMAGXYQPWSDN-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- QJFJBHYIIFGMSF-UHFFFAOYSA-N 6-[2-methyl-4-[[5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SC=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=CC=CC=C1OC(F)(F)F QJFJBHYIIFGMSF-UHFFFAOYSA-N 0.000 claims 2
- ZZIKYOSVNOPNQR-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]-1-propan-2-ylindazole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C(C)C)N=C(C3=CC=2)C(O)=O)C=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl ZZIKYOSVNOPNQR-UHFFFAOYSA-N 0.000 claims 2
- UUYQPCIBFJNDPY-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SC=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl UUYQPCIBFJNDPY-UHFFFAOYSA-N 0.000 claims 2
- WRYFJPMYDZTZDM-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]-1,2-benzothiazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NSC2=CC=1C(C=C1)=CC=C1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F WRYFJPMYDZTZDM-UHFFFAOYSA-N 0.000 claims 2
- JYOCNKHJCKGZQQ-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]-1-methylindazole-3-carboxylic acid Chemical compound C1=C2N(C)N=C(C(O)=O)C2=CC=C1C(C=C1)=CC=C1OCC=1C(C=2C(=CC=CC=2)OC(F)(F)F)=NOC=1C1CC1 JYOCNKHJCKGZQQ-UHFFFAOYSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical class O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- GIHONUTUAVSZKH-UHFFFAOYSA-N 1,1,1-trifluoro-2-methoxypropan-2-ol Chemical compound COC(C)(O)C(F)(F)F GIHONUTUAVSZKH-UHFFFAOYSA-N 0.000 claims 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- UDHVEBAZALTEPC-UHFFFAOYSA-N 2-[2-methyl-4-[[5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]-1,3-thiazole-5-carboxylic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2)OC(F)(F)F)C=1COC(C=C1C)=CC=C1C1=NC=C(C(O)=O)S1 UDHVEBAZALTEPC-UHFFFAOYSA-N 0.000 claims 1
- TUMQNQFLMXIJAC-UHFFFAOYSA-N 2-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(C)N=C1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl TUMQNQFLMXIJAC-UHFFFAOYSA-N 0.000 claims 1
- FVELTSYVRUDGOY-UHFFFAOYSA-N 2-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-4-propan-2-yl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(C(C)C)N=C1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl FVELTSYVRUDGOY-UHFFFAOYSA-N 0.000 claims 1
- WTVHUEAULKJHLB-UHFFFAOYSA-N 2-[4-[[5-cyclopropyl-3-[2-fluoro-6-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(C)N=C1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=C(F)C=CC=C1C(F)(F)F WTVHUEAULKJHLB-UHFFFAOYSA-N 0.000 claims 1
- VXJUTMUZMNGPBO-UHFFFAOYSA-N 5-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-4-methylthiophene-2-carboxylic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(C=C1C)=CC=C1C=1SC(C(O)=O)=CC=1C VXJUTMUZMNGPBO-UHFFFAOYSA-N 0.000 claims 1
- QWJGNTHOQWQFFL-UHFFFAOYSA-N 5-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-4-methylthiophene-2-carboxylic acid Chemical compound C1=C(C(O)=O)SC(C=2C(=CC(OCC=3C(=NOC=3C3CC3)C=3C(=CC=CC=3Cl)Cl)=CC=2)C)=C1C QWJGNTHOQWQFFL-UHFFFAOYSA-N 0.000 claims 1
- CDHJFALRGJMKIE-UHFFFAOYSA-N 5-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]thiophene-2-carboxylic acid Chemical compound C=1C=C(C=2SC(=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl CDHJFALRGJMKIE-UHFFFAOYSA-N 0.000 claims 1
- HVNUKGZWVMJPJF-UHFFFAOYSA-N 5-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]thiophene-2-carboxylic acid Chemical compound C=1C=C(C=2SC(=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F HVNUKGZWVMJPJF-UHFFFAOYSA-N 0.000 claims 1
- YABZYGXGQPZIAS-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1,2-dimethylindole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C)C(C)=C(C(O)=O)C3=CC=2)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl YABZYGXGQPZIAS-UHFFFAOYSA-N 0.000 claims 1
- DJIPMJOPIWKCLD-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SC=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl DJIPMJOPIWKCLD-UHFFFAOYSA-N 0.000 claims 1
- CBZGTSZJINLFEQ-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-methylindole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C)C=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl CBZGTSZJINLFEQ-UHFFFAOYSA-N 0.000 claims 1
- OOOHZAYEJFWVSE-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-2-methyl-1-benzofuran-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3OC(C)=C(C(O)=O)C3=CC=2)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl OOOHZAYEJFWVSE-UHFFFAOYSA-N 0.000 claims 1
- PVQOIMYKUJFHSV-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]-1,2-benzothiazole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SN=C(C3=CC=2)C(O)=O)C=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl PVQOIMYKUJFHSV-UHFFFAOYSA-N 0.000 claims 1
- RBASMHPZQAJQJT-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]-1-methylindazole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C)N=C(C3=CC=2)C(O)=O)C=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl RBASMHPZQAJQJT-UHFFFAOYSA-N 0.000 claims 1
- XAAWGJUGXCHHTM-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1,2-benzoxazole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3ON=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC=1C(C=2C(=CC=CC=2Cl)Cl)=NOC=1C1CC1 XAAWGJUGXCHHTM-UHFFFAOYSA-N 0.000 claims 1
- QOSBUFDWTQHHPA-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-methylindole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C)C=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl QOSBUFDWTQHHPA-UHFFFAOYSA-N 0.000 claims 1
- XIKIQAPAEXOOSR-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-1,2-benzothiazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NSC2=CC=1C(C=C1)=CC=C1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl XIKIQAPAEXOOSR-UHFFFAOYSA-N 0.000 claims 1
- HQWMJWTYHIPJEE-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1,2-dimethylindole-3-carboxylic acid Chemical compound C1=C2N(C)C(C)=C(C(O)=O)C2=CC=C1C(C(=C1)C)=CC=C1OCC=1C(C=2C(=CC=CC=2)OC(F)(F)F)=NOC=1C1CC1 HQWMJWTYHIPJEE-UHFFFAOYSA-N 0.000 claims 1
- ZOHJLACFQDZGGA-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-methylindole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C)C=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F ZOHJLACFQDZGGA-UHFFFAOYSA-N 0.000 claims 1
- YDYNTEWMHLSXMZ-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-propan-2-ylindole-3-carboxylic acid Chemical compound C1=C2N(C(C)C)C=C(C(O)=O)C2=CC=C1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F YDYNTEWMHLSXMZ-UHFFFAOYSA-N 0.000 claims 1
- ONXZEWJFFDMQDE-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-2-methyl-1-benzofuran-3-carboxylic acid Chemical compound C=1C=C2C(C(O)=O)=C(C)OC2=CC=1C(C(=C1)C)=CC=C1OCC=1C(C=2C(=CC=CC=2)OC(F)(F)F)=NOC=1C1CC1 ONXZEWJFFDMQDE-UHFFFAOYSA-N 0.000 claims 1
- UICHUVJHVIHQHD-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-2-methyl-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C2C(C(O)=O)=C(C)SC2=CC=1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F UICHUVJHVIHQHD-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- JNGDFYLGDPAEBY-UHFFFAOYSA-N oxadiazole-4-thione Chemical compound S=C1CON=N1 JNGDFYLGDPAEBY-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- XWMXMWHHTIEXRE-UHFFFAOYSA-N thiadiazole 1-oxide Chemical compound O=S1C=CN=N1 XWMXMWHHTIEXRE-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76540706P | 2006-02-03 | 2006-02-03 | |
| US60/765,407 | 2006-02-03 | ||
| US80631006P | 2006-06-30 | 2006-06-30 | |
| US60/806,310 | 2006-06-30 | ||
| PCT/US2007/061515 WO2007092751A2 (en) | 2006-02-03 | 2007-02-02 | Compounds and methods for modulating fx-receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009525984A JP2009525984A (ja) | 2009-07-16 |
| JP2009525984A5 true JP2009525984A5 (enExample) | 2013-02-21 |
| JP5301286B2 JP5301286B2 (ja) | 2013-09-25 |
Family
ID=38229980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553518A Active JP5301286B2 (ja) | 2006-02-03 | 2007-02-02 | Ｆｘ受容体を調節するための化合物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7863302B2 (enExample) |
| EP (1) | EP1984360B1 (enExample) |
| JP (1) | JP5301286B2 (enExample) |
| CN (1) | CN101374834B (enExample) |
| AU (1) | AU2007212126B2 (enExample) |
| BR (1) | BRPI0707427A2 (enExample) |
| CA (1) | CA2640476A1 (enExample) |
| ES (1) | ES2452031T3 (enExample) |
| WO (1) | WO2007092751A2 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2374165T3 (es) * | 2005-12-19 | 2012-02-14 | Glaxosmithkline Llc | Agonistas del receptor x farnesoide. |
| JP4999923B2 (ja) * | 2006-06-13 | 2012-08-15 | 中国科学院上海薬物研究所 | 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物 |
| EP2170072A4 (en) * | 2007-06-13 | 2010-10-27 | Glaxosmithkline Llc | Farnesoid X RECEPTOR AGONISTS |
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| MX2010005753A (es) | 2007-12-04 | 2010-06-15 | Hoffmann La Roche | Derivados de isoxazolo-pirazina. |
| US7902201B2 (en) | 2007-12-04 | 2011-03-08 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| EA020460B1 (ru) | 2009-01-12 | 2014-11-28 | Пфайзер Лимитед | Производные сульфонамида |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
| EP2427455B1 (en) | 2009-05-05 | 2020-01-15 | F.Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
| BRPI1011729A2 (pt) | 2009-05-05 | 2016-03-15 | Hoffmann La Roche | derivados de isoxazol-tiazol como um receptor inverso gaba a agonista para uso no tratamento de distúrbios cognitivos |
| SG175867A1 (en) | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-pyridine derivatives |
| AU2010244545A1 (en) | 2009-05-05 | 2011-10-13 | F. Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
| AU2010244555A1 (en) | 2009-05-07 | 2011-11-03 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as GABA modulators |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2569301A1 (en) | 2010-05-12 | 2013-03-20 | Abbvie Inc. | Indazole inhibitors of kinase |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| WO2012087521A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| EP2655368A1 (en) * | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| AP3649A (en) | 2011-02-23 | 2016-03-18 | Lupin Ltd | Heteroaryl derivatives as alpha7 nachr modulators |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2729455B1 (en) | 2011-07-05 | 2016-09-14 | Lupin Limited | Biaryl derivatives as nachr modulators |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8785435B2 (en) | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
| JP6106179B2 (ja) | 2012-02-24 | 2017-03-29 | 武田薬品工業株式会社 | 芳香環化合物 |
| IN2014MN01756A (enExample) | 2012-03-06 | 2015-07-03 | Lupin Ltd | |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| JP6366721B2 (ja) | 2013-09-11 | 2018-08-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| MA41094A (fr) * | 2014-12-02 | 2017-10-10 | Lilly Co Eli | Procédés de traitement de troubles rénaux |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| SI3277286T1 (sl) | 2015-03-31 | 2021-09-30 | Enanta Pharmaceuticals, Inc. | Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo |
| WO2017128896A1 (zh) * | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
| CN106995416A (zh) * | 2016-01-26 | 2017-08-01 | 上海翰森生物医药科技有限公司 | Fxr激动剂及其制备方法和应用 |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
| ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| EP3523298A4 (en) * | 2016-10-04 | 2020-06-24 | Enanta Pharmaceuticals, Inc. | ISOXAZOLANALOGA AS FXR AGONISTS AND METHOD FOR USE THEREOF |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| WO2018133730A1 (zh) * | 2017-01-20 | 2018-07-26 | 四川科伦博泰生物医药股份有限公司 | 一种杂环化合物及其制备方法和用途 |
| EP4424364B1 (en) | 2017-03-28 | 2026-01-21 | Gilead Sciences, Inc. | Combinations for use in the treatment of cirrhosis and liver fibrosis |
| EP3600293A1 (en) | 2017-03-30 | 2020-02-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| SI3612520T1 (sl) | 2017-04-12 | 2022-01-31 | Il Dong Pharmaceutical Co., Ltd. | Izoksazolni derivati kot agonisti nuklearnega receptorja in njihove uporabe |
| CN106977535A (zh) * | 2017-04-28 | 2017-07-25 | 大连联化化学有限公司 | 一种合成2‑氰基3‑氟苯硼酸工艺 |
| CN109575008B (zh) * | 2017-09-29 | 2020-11-17 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| KR102732404B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 |
| CN111630051B (zh) | 2017-11-01 | 2023-12-26 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的烯烃螺环化合物 |
| KR102731925B1 (ko) | 2017-11-01 | 2024-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| PE20211907A1 (es) | 2019-01-15 | 2021-09-28 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| KR102725082B1 (ko) | 2019-02-19 | 2024-11-04 | 길리애드 사이언시즈, 인코포레이티드 | Fxr 효능제의 고체 형태 |
| CN111825667B (zh) * | 2019-04-19 | 2023-07-25 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| CN111004211B (zh) * | 2019-12-29 | 2021-04-02 | 苏州诚和医药化学有限公司 | 一种依匹哌唑中间体4-溴苯并［b］噻吩的合成方法 |
| WO2021145543A1 (ko) * | 2020-01-15 | 2021-07-22 | 재단법인 대구경북과학기술원 | 세포외 기질 및 항암제로 이루어진 접합체 및 이의 의학적 용도 |
| US20230060715A1 (en) | 2020-01-15 | 2023-03-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| US20240100125A1 (en) | 2021-01-14 | 2024-03-28 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| CN112876516B (zh) * | 2021-02-05 | 2022-02-15 | 昆明理工大学 | N-(4-吲哚基)氮杂环卡宾钯络合物及应用 |
| CN112898247B (zh) * | 2021-03-09 | 2023-03-14 | 中国科学院兰州化学物理研究所 | 一种呋喃乙酸酯类化合物的合成方法 |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
| CN116425716A (zh) * | 2021-12-31 | 2023-07-14 | 南京艾德凯腾生物医药有限责任公司 | 一种依匹哌唑中间体的制备方法 |
| CN115850152B (zh) * | 2022-12-20 | 2025-10-31 | 河北鼎泰制药有限公司 | 一种杂质A-7-imp3的制备方法及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| EP1562915A1 (en) | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x receptor agonists |
| ES2374165T3 (es) * | 2005-12-19 | 2012-02-14 | Glaxosmithkline Llc | Agonistas del receptor x farnesoide. |
-
2007
- 2007-02-02 BR BRPI0707427-1A patent/BRPI0707427A2/pt not_active IP Right Cessation
- 2007-02-02 AU AU2007212126A patent/AU2007212126B2/en not_active Ceased
- 2007-02-02 CA CA002640476A patent/CA2640476A1/en not_active Abandoned
- 2007-02-02 CN CN2007800038562A patent/CN101374834B/zh not_active Expired - Fee Related
- 2007-02-02 WO PCT/US2007/061515 patent/WO2007092751A2/en not_active Ceased
- 2007-02-02 US US12/159,224 patent/US7863302B2/en active Active
- 2007-02-02 JP JP2008553518A patent/JP5301286B2/ja active Active
- 2007-02-02 EP EP07763142.2A patent/EP1984360B1/en active Active
- 2007-02-02 ES ES07763142.2T patent/ES2452031T3/es active Active